Új-Zéland - angol - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin;  ; bicalutamide 50mg - combination - 10.8mg+50mg pack - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin   excipient: polyglactin active: bicalutamide 50mg excipient: hypromellose lactose macrogol 300 magnesium stearate povidone sodium starch glycolate titanium dioxide - zolacos cp is indicated for the treatment of advanced prostate cancer and prevention of disease flare associated with the use of lhrh agonists.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 3.8mg equivalent to 3.6 mg goserelin;  ; bicalutamide 50mg;   - combination - 3.6mg + 50mg pack - active: goserelin acetate 3.8mg equivalent to 3.6 mg goserelin   excipient: polyglactin active: bicalutamide 50mg   excipient: hypromellose lactose macrogol 300 magnesium stearate povidone sodium starch glycolate titanium dioxide - zolacos cp is indicated for the treatment of advanced prostate cancer and prevention of disease flare associated with the use of lhrh agonists.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin;   - injection (depot) - 10.8 mg - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin   excipient: polyglactin - zoladex 10.8 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 3.8mg equivalent to 3.6 mg goserelin;   - injection (depot) - 3.6 mg - active: goserelin acetate 3.8mg equivalent to 3.6 mg goserelin   excipient: polyglactin - zoladex 3.6 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.

Kanada - angol - Health Canada

tersera therapeutics llc - goserelin (goserelin acetate) - implant - 3.6mg - goserelin (goserelin acetate) 3.6mg - gonadotropins and antigonadotropins

Kanada - angol - Health Canada

tersera therapeutics llc - goserelin (goserelin acetate) - implant - 10.8mg - goserelin (goserelin acetate) 10.8mg - miscellaneous therapeutic agents

Egyesült Államok - angol - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - goserelin acetate (unii: 6yuu2pv0u8) (goserelin - unii:0f65r8p09n) - goserelin 3.6 mg - zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b-t4 (stage b2-c) carcinoma of the prostate. treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see dosage and administration (2.1) and clinical studies (14.1)]. zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate [see dosage and administration (2.2) and clinical studies (14.2)]. zoladex is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see dosage and administration (2.3) and clinical studies (14.3)]. zoladex is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see dosage and administration (2.4) and cl

Egyesült Államok - angol - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - goserelin acetate (unii: 6yuu2pv0u8) (goserelin - unii:0f65r8p09n) - goserelin 10.8 mg - zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b-t4 (stage b2-c) carcinoma of the prostate. treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see dosage and administration (2.1) and clinical studies (14.1)]. zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate [see dosage and administration (2.2) and clinical studies (14.2)] . in controlled studies of patients with advanced prostatic cancer comparing zoladex 3.6 mg to orchiectomy, the long-term endocrine responses and objective responses were similar between the two treatment arms. additionally, duration of survival was similar between the two treatment arms in a major comparative trial. in controlled studies of patients with advanced prostatic cancer, zoladex 10.8 mg implant produced pharmacodynamically similar effect in terms of suppression of serum testosterone to that achieved wit

Egyesült Államok - angol - NLM (National Library of Medicine)

a-s medication solutions - goserelin acetate (unii: 6yuu2pv0u8) (goserelin - unii:0f65r8p09n) - goserelin 3.6 mg - zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b-t4 (stage b2-c) carcinoma of the prostate. treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see dosage and administration (2.1) and clinical studies (14.1)]. zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate [see dosage and administration (2.2) and clinical studies (14.2)]. zoladex is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see dosage and administration (2.3) and clinical studies (14.3)]. zoladex is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see dosage and administration (2.4) and cl

Egyesült Államok - angol - NLM (National Library of Medicine)

tersera therapeutics llc - goserelin acetate (unii: 6yuu2pv0u8) (goserelin - unii:0f65r8p09n) - goserelin 3.6 mg - zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b-t4 (stage b2-c) carcinoma of the prostate. treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see dosage and administration (2.1) and clinical studies (14.1)]. zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate [see dosage and administration (2.2) and clinical studies (14.2)]. zoladex is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see dosage and administration (2.3) and clinical studies (14.3)]. zoladex is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see dosage and administration (2.4) and cl